The effect of pathophysiology on the outcome of mitral valve repair for mitral regurgitation

Chiao Po Hsu, Shiao Hwang Chang, Ming Chi Yung, Jih Shiuan Wang, Chun Che Shih, Cheng Hsiung Hwang, Zen Chung Weng, Tarng Jenn Yu, Shiau Ting Lai

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The advantages of mitral valve repair in mitral regurgitation are well established. The aim of this study was to analyze retrospectively the early and mid-term results of primary mitral valve repair. Between January 1995 and August 2001, primary mitral valve repair operations were performed on 112 patients (76 men and 36 women) with mitral regurgitation; the mean age was 59.8 ± 16.5 years. Mitral valve repair was performed for rheumatic heart disease (13), degenerative disease (60), infective endocarditis (2), ischemic heart disease (26), congenital heart disease (2), and dilated cardiomyopathy (9). The degree of mitral regurgitation was moderate in 28 patients, moderately severe in 17 patients, and severe in 67 patients, as determined by echocardiography. Left ventricular ejection fraction (mean 41.2% ± 13.5%) was measured by radionuclide ventriculography. Fifty percent of patients underwent additional procedures (e.g., coronary artery bypass grafting). The mortality rate was 8.9% (10/112) for hospitalized patients, 19.2% (5/26) for ischemic disease, and 5% (3/60) for degenerative disease. Follow-up duration ranged from 0.37 to 84.03 months. All survivors were evaluated with serial echocardiography. At the final follow-up echocardiography of 94 patients without reoperation and 6 patients at the time of reoperation, 84% had no or mild mitral regurgitation. The survival rate at 5 years was 92.68 ± 3.57% for degenerative disease and 44.47% ± 10.89% for ischemic disease. The risk of infective endocarditis (1.78%), thromboembolism (1.78%), and anticoagulant-related complications (0.8%) was very low during the follow-up period. The pathophysiological mechanism resulting in mitral regurgitation was the most important determinant of outcome after mitral valve repair. Excellent results were achieved with mitral valve repair for degenerative disease. Because of low morbidity and acceptable mortality, we strongly recommend mitral valve repair for mitral regurgitation due to degenerative disease.

Original languageEnglish
Pages (from-to)27-32
Number of pages6
JournalHeart and Vessels
Volume19
Issue number1
DOIs
Publication statusPublished - Jan 1 2004
Externally publishedYes

Fingerprint

Mitral Valve Insufficiency
Mitral Valve
Echocardiography
Endocarditis
Reoperation
Radionuclide Ventriculography
Rheumatic Heart Disease
Mortality
Thromboembolism
Dilated Cardiomyopathy
Coronary Artery Bypass
Stroke Volume
Anticoagulants
Myocardial Ischemia
Survivors
Heart Diseases
Survival Rate
Morbidity

Keywords

  • Mitral regurgitation
  • Mitral valve repair

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

The effect of pathophysiology on the outcome of mitral valve repair for mitral regurgitation. / Hsu, Chiao Po; Chang, Shiao Hwang; Yung, Ming Chi; Wang, Jih Shiuan; Shih, Chun Che; Hwang, Cheng Hsiung; Weng, Zen Chung; Yu, Tarng Jenn; Lai, Shiau Ting.

In: Heart and Vessels, Vol. 19, No. 1, 01.01.2004, p. 27-32.

Research output: Contribution to journalArticle

Hsu, Chiao Po ; Chang, Shiao Hwang ; Yung, Ming Chi ; Wang, Jih Shiuan ; Shih, Chun Che ; Hwang, Cheng Hsiung ; Weng, Zen Chung ; Yu, Tarng Jenn ; Lai, Shiau Ting. / The effect of pathophysiology on the outcome of mitral valve repair for mitral regurgitation. In: Heart and Vessels. 2004 ; Vol. 19, No. 1. pp. 27-32.
@article{eb8fe0cf3f2b484b93f49d8468de39ea,
title = "The effect of pathophysiology on the outcome of mitral valve repair for mitral regurgitation",
abstract = "The advantages of mitral valve repair in mitral regurgitation are well established. The aim of this study was to analyze retrospectively the early and mid-term results of primary mitral valve repair. Between January 1995 and August 2001, primary mitral valve repair operations were performed on 112 patients (76 men and 36 women) with mitral regurgitation; the mean age was 59.8 ± 16.5 years. Mitral valve repair was performed for rheumatic heart disease (13), degenerative disease (60), infective endocarditis (2), ischemic heart disease (26), congenital heart disease (2), and dilated cardiomyopathy (9). The degree of mitral regurgitation was moderate in 28 patients, moderately severe in 17 patients, and severe in 67 patients, as determined by echocardiography. Left ventricular ejection fraction (mean 41.2{\%} ± 13.5{\%}) was measured by radionuclide ventriculography. Fifty percent of patients underwent additional procedures (e.g., coronary artery bypass grafting). The mortality rate was 8.9{\%} (10/112) for hospitalized patients, 19.2{\%} (5/26) for ischemic disease, and 5{\%} (3/60) for degenerative disease. Follow-up duration ranged from 0.37 to 84.03 months. All survivors were evaluated with serial echocardiography. At the final follow-up echocardiography of 94 patients without reoperation and 6 patients at the time of reoperation, 84{\%} had no or mild mitral regurgitation. The survival rate at 5 years was 92.68 ± 3.57{\%} for degenerative disease and 44.47{\%} ± 10.89{\%} for ischemic disease. The risk of infective endocarditis (1.78{\%}), thromboembolism (1.78{\%}), and anticoagulant-related complications (0.8{\%}) was very low during the follow-up period. The pathophysiological mechanism resulting in mitral regurgitation was the most important determinant of outcome after mitral valve repair. Excellent results were achieved with mitral valve repair for degenerative disease. Because of low morbidity and acceptable mortality, we strongly recommend mitral valve repair for mitral regurgitation due to degenerative disease.",
keywords = "Mitral regurgitation, Mitral valve repair",
author = "Hsu, {Chiao Po} and Chang, {Shiao Hwang} and Yung, {Ming Chi} and Wang, {Jih Shiuan} and Shih, {Chun Che} and Hwang, {Cheng Hsiung} and Weng, {Zen Chung} and Yu, {Tarng Jenn} and Lai, {Shiau Ting}",
year = "2004",
month = "1",
day = "1",
doi = "10.1007/s00380-003-0728-6",
language = "English",
volume = "19",
pages = "27--32",
journal = "Heart and Vessels",
issn = "0910-8327",
publisher = "Springer Japan",
number = "1",

}

TY - JOUR

T1 - The effect of pathophysiology on the outcome of mitral valve repair for mitral regurgitation

AU - Hsu, Chiao Po

AU - Chang, Shiao Hwang

AU - Yung, Ming Chi

AU - Wang, Jih Shiuan

AU - Shih, Chun Che

AU - Hwang, Cheng Hsiung

AU - Weng, Zen Chung

AU - Yu, Tarng Jenn

AU - Lai, Shiau Ting

PY - 2004/1/1

Y1 - 2004/1/1

N2 - The advantages of mitral valve repair in mitral regurgitation are well established. The aim of this study was to analyze retrospectively the early and mid-term results of primary mitral valve repair. Between January 1995 and August 2001, primary mitral valve repair operations were performed on 112 patients (76 men and 36 women) with mitral regurgitation; the mean age was 59.8 ± 16.5 years. Mitral valve repair was performed for rheumatic heart disease (13), degenerative disease (60), infective endocarditis (2), ischemic heart disease (26), congenital heart disease (2), and dilated cardiomyopathy (9). The degree of mitral regurgitation was moderate in 28 patients, moderately severe in 17 patients, and severe in 67 patients, as determined by echocardiography. Left ventricular ejection fraction (mean 41.2% ± 13.5%) was measured by radionuclide ventriculography. Fifty percent of patients underwent additional procedures (e.g., coronary artery bypass grafting). The mortality rate was 8.9% (10/112) for hospitalized patients, 19.2% (5/26) for ischemic disease, and 5% (3/60) for degenerative disease. Follow-up duration ranged from 0.37 to 84.03 months. All survivors were evaluated with serial echocardiography. At the final follow-up echocardiography of 94 patients without reoperation and 6 patients at the time of reoperation, 84% had no or mild mitral regurgitation. The survival rate at 5 years was 92.68 ± 3.57% for degenerative disease and 44.47% ± 10.89% for ischemic disease. The risk of infective endocarditis (1.78%), thromboembolism (1.78%), and anticoagulant-related complications (0.8%) was very low during the follow-up period. The pathophysiological mechanism resulting in mitral regurgitation was the most important determinant of outcome after mitral valve repair. Excellent results were achieved with mitral valve repair for degenerative disease. Because of low morbidity and acceptable mortality, we strongly recommend mitral valve repair for mitral regurgitation due to degenerative disease.

AB - The advantages of mitral valve repair in mitral regurgitation are well established. The aim of this study was to analyze retrospectively the early and mid-term results of primary mitral valve repair. Between January 1995 and August 2001, primary mitral valve repair operations were performed on 112 patients (76 men and 36 women) with mitral regurgitation; the mean age was 59.8 ± 16.5 years. Mitral valve repair was performed for rheumatic heart disease (13), degenerative disease (60), infective endocarditis (2), ischemic heart disease (26), congenital heart disease (2), and dilated cardiomyopathy (9). The degree of mitral regurgitation was moderate in 28 patients, moderately severe in 17 patients, and severe in 67 patients, as determined by echocardiography. Left ventricular ejection fraction (mean 41.2% ± 13.5%) was measured by radionuclide ventriculography. Fifty percent of patients underwent additional procedures (e.g., coronary artery bypass grafting). The mortality rate was 8.9% (10/112) for hospitalized patients, 19.2% (5/26) for ischemic disease, and 5% (3/60) for degenerative disease. Follow-up duration ranged from 0.37 to 84.03 months. All survivors were evaluated with serial echocardiography. At the final follow-up echocardiography of 94 patients without reoperation and 6 patients at the time of reoperation, 84% had no or mild mitral regurgitation. The survival rate at 5 years was 92.68 ± 3.57% for degenerative disease and 44.47% ± 10.89% for ischemic disease. The risk of infective endocarditis (1.78%), thromboembolism (1.78%), and anticoagulant-related complications (0.8%) was very low during the follow-up period. The pathophysiological mechanism resulting in mitral regurgitation was the most important determinant of outcome after mitral valve repair. Excellent results were achieved with mitral valve repair for degenerative disease. Because of low morbidity and acceptable mortality, we strongly recommend mitral valve repair for mitral regurgitation due to degenerative disease.

KW - Mitral regurgitation

KW - Mitral valve repair

UR - http://www.scopus.com/inward/record.url?scp=0346786469&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0346786469&partnerID=8YFLogxK

U2 - 10.1007/s00380-003-0728-6

DO - 10.1007/s00380-003-0728-6

M3 - Article

C2 - 14685752

AN - SCOPUS:0346786469

VL - 19

SP - 27

EP - 32

JO - Heart and Vessels

JF - Heart and Vessels

SN - 0910-8327

IS - 1

ER -